human B cell-depleting agent. Third-generation anti-CD20s such as obinutuzumab have a glycoengineered Fc fragment (Fc) with enhanced binding to Fc gamma receptors, which increase ADCC (antibody-dependent cellular cytotoxicity). This strategy for enhancing a monoclonal antibody's ability to induce ADCC takes advantage of the fact that the displayed Fc glycan controls the antibody's affinity for Fc receptors. References External links Genentech brands Hoffmann-La Roche brands Monoclonal antibodies for tumors Orphan drugs Specialty drugs World Health Organization essential medicines Wikipedia medicine articles ready to translate